New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists

Amgen Inc.Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world's leading universities. Now, the Amgen Scholars - past, present and future - will have exclusive access to the online Amgen Scholars Community.

"The new Web site is designed to connect, engage and inspire Amgen Scholars on a global level by bringing together participants from diverse backgrounds and wide-ranging scientific career aspirations," said Jean J. Lim, president of the Amgen Foundation. "We hope that the online community will enrich the experience for all Amgen Scholars, not only during the program, but throughout their future careers in science."

The new Web site, launched in partnership with The Scientist, a leading life sciences magazine, allows current Amgen Scholars and alumni to login and access tools aimed at helping them build professional networks and read the latest science and career news. Through the use of interactive polls, message boards, personal profiles and blogs, users can discuss their participation in the program and various science-related topics such as graduate education and career paths in research. Others interested in the program can also view past participant and faculty mentor profiles and read excerpts of student blogs from the online community in the publicly-accessible section of the site.

2010 Amgen Scholars Program Applications Now Available
Established in 2006, Amgen Scholars is a $27.5 million initiative that provides undergraduates with the opportunity for hands-on research at some of the world's leading institutions. The opportunity to work with top academic scientists is a cornerstone of the program, with participating universities seeking to match students with faculty members who will both inspire and challenge them. In addition, the U.S. and Europe programs each host a three-day symposium allowing students to share their summer research projects and hear firsthand from leading industry and academic scientists.

To date, more than 800 undergraduates have participated in the Amgen Scholars Program. Considered among the most competitive summer research programs in the U.S., several Amgen Scholar alumni have gone on to pursue doctorates at leading universities with some being selected for premier fellowships including the Rhodes Scholarships.

In the U.S., the host universities are California Institute of Technology; Columbia University/Barnard College; Howard University; MIT; Stanford University; University of California, Berkeley; UCLA; University of California, San Diego; University of California, San Francisco; and University of Washington. In Europe, the participating universities are the University of Cambridge; Karolinska Institute; and Ludwig-Maximilians-University.

Financial support for students is a critical component of the U.S. and Europe programs, which aims to ensure that eligible students, regardless of their financial status, are able to participate. Please note that details vary by host university.

For more information about Amgen Scholars including eligibility criteria and applications, please visit www.amgenscholars.com.

About the Amgen Foundation
The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made $130 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts internationally.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...